Predictors of random sextant biopsy outcome in screened men with PSA >4 ng/mL and a negative sextant biopsy at previous screening.: Experience in a population-based screening program in Florence

被引:6
作者
Ciatto, S
Lombardi, C
Rubeca, T
Zappa, A
机构
[1] Ctr Studio & Prevenz Oncol, I-50131 Florence, Italy
[2] Torre Galli Hosp, Dept Urol, Florence, Italy
关键词
prostate carcinoma; prostate-specific antigen; random biopsy; diagnosis;
D O I
10.1177/172460080401900201
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The aim of this study was to evaluate possible pedictors of the outcome of repeat random sextant biopsy of the prostate prompted by a rise in prostate-specific antigen (PSA). Random biopsies performed for PSA elevation (>4 ng/mL) in the course of a randomized study of screening efficacy were reviewed, and 87 consecutive biopsies (carcinoma=13, high-grade prostatic intraepithelial neoplasia=6, negative=68) performed in subjects with a negative random biopsy at the previous screening round were considered. Findings at digital rectal examination or transrectal ultrasonography and total PSA value were not useful predictors of repeat biopsy outcome, whereas PSA velocity was significantly associated with biopsy outcome. The positive predictive value for a cancer biopsy was 2.7% (1/36), 28.5% (2/7), and 22.7% (10/44) for PSA velocity values of <0.1, 0.1-0.19, and >0.19 ng/mL/yr, respectively. A cutoff of 0.1 ng/mL/yr for PSA velocity would have allowed to avoid approximately half (35/74=47.2%) of the benign biopsies while decreasing the sensitivity by 7.6% (1/13), and is thus suggested as a possible criterion for the indication of repeat random biopsy for persistent PSA elevation.
引用
收藏
页码:89 / 92
页数:4
相关论文
共 12 条
[1]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[2]   COMPARING 2 MODALITIES OF SCREENING FOR PROSTATE-CANCER - DIGITAL RECTAL EXAMINATION PLUS TRANSRECTAL ULTRASONOGRAPHY VS PROSTATE-SPECIFIC ANTIGEN [J].
CIATTO, S ;
BONARDI, R ;
MAZZOTTA, A ;
LOMBARDI, C ;
SANTONI, R ;
CARDINI, S ;
ZAPPA, M .
TUMORI, 1995, 81 (04) :225-229
[3]   Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds [J].
Ciatto, S ;
Bonardi, R ;
Lombardi, C ;
Zappa, A ;
Gervasi, G ;
Cappelli, G .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (02) :79-83
[4]   Screening for prostate cancer by PSA determination: a time for caution [J].
Ciatto, S .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (04) :285-287
[5]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[6]   Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate [J].
Eskew, LA ;
Bare, RL ;
McCullough, DL .
JOURNAL OF UROLOGY, 1997, 157 (01) :199-202
[7]   Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? [J].
Lefkowitz, GK ;
Sidhu, GS ;
Torre, P ;
Lepor, H ;
Taneja, SS .
UROLOGY, 2001, 58 (06) :999-1003
[8]  
Mäkinen T, 2002, UROLOGY, V60, P846
[9]  
OESTERLING JE, 1993, UROL CLIN N AM, V20, P671
[10]   Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program [J].
Raaijmakers, R ;
Kirkels, WJ ;
Roobol, MJ ;
Wildhagen, MF ;
Schröder, FH .
UROLOGY, 2002, 60 (05) :826-830